These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 2334921

  • 1. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.
    Hantel A, Donehower RC, Rowinsky EK, Vance E, Clarke BV, McGuire WP, Ettinger DS, Noe DA, Grochow LB.
    Cancer Res; 1990 Jun 01; 50(11):3284-8. PubMed ID: 2334921
    [Abstract] [Full Text] [Related]

  • 2. Phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole, CI-937 (DUP937).
    Erlichman C, Moore M, Kerr IG, Wong B, Eisenhauer E, Zee B, Whitfield LR.
    Cancer Res; 1991 Dec 01; 51(23 Pt 1):6317-22. PubMed ID: 1933893
    [Abstract] [Full Text] [Related]

  • 3. A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
    Diab SG, Baker SD, Joshi A, Burris HA, Cobb PW, Villalona-Calero MA, Eckhardt SG, Weiss GR, Rodriguez GI, Drengler R, Kraynak M, Hammond L, Finizio M, Von Hoff DD, Rowinsky EK.
    Clin Cancer Res; 1999 Feb 01; 5(2):299-308. PubMed ID: 10037178
    [Abstract] [Full Text] [Related]

  • 4. Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme.
    Graham MA, Newell DR, Foster BJ, Gumbrell LA, Jenns KE, Calvert AH.
    Cancer Res; 1992 Feb 01; 52(3):603-9. PubMed ID: 1732048
    [Abstract] [Full Text] [Related]

  • 5. Phase I and clinical pharmacological evaluation of pirozantrone hydrochloride (oxantrazole).
    Ames MM, Loprinzi CL, Collins JM, van Haelst-Pisani C, Richardson RL, Rubin J, Moertel CG.
    Cancer Res; 1990 Jul 01; 50(13):3905-9. PubMed ID: 2191768
    [Abstract] [Full Text] [Related]

  • 6. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
    Dees EC, Whitfield LR, Grove WR, Rummel S, Grochow LB, Donehower RC.
    Clin Cancer Res; 2000 Oct 01; 6(10):3885-94. PubMed ID: 11051234
    [Abstract] [Full Text] [Related]

  • 7. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
    LoRusso P, Foster BJ, Poplin E, McCormick J, Kraut M, Flaherty L, Heilbrun LK, Valdivieso M, Baker L.
    Clin Cancer Res; 1995 Dec 01; 1(12):1487-93. PubMed ID: 9815948
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of piroxantrone in a phase I trial of piroxantrone and granulocyte-colony stimulating factor.
    Berg SL, Savarese DM, Balis FM, Denicoff AM, Hillig M, O'Shaughnessy JA, Poplack DG, Cowan KH.
    Cancer Res; 1993 Jun 01; 53(11):2587-90. PubMed ID: 7684320
    [Abstract] [Full Text] [Related]

  • 9. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.
    Pitot HC, McElroy EA, Reid JM, Windebank AJ, Sloan JA, Erlichman C, Bagniewski PG, Walker DL, Rubin J, Goldberg RM, Adjei AA, Ames MM.
    Clin Cancer Res; 1999 Mar 01; 5(3):525-31. PubMed ID: 10100703
    [Abstract] [Full Text] [Related]

  • 10. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
    Sasaki Y, Amano T, Morita M, Shinkai T, Eguchi K, Tamura T, Ohe Y, Kojima A, Saijo N.
    Cancer Res; 1991 Mar 01; 51(5):1472-7. PubMed ID: 1997185
    [Abstract] [Full Text] [Related]

  • 11. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG, Balcerzak SP, Kraut EH.
    Cancer Res; 1993 Oct 15; 53(20):4843-9. PubMed ID: 8402671
    [Abstract] [Full Text] [Related]

  • 12. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
    Vogelzang NJ, Mick R, Janisch L, Berezin F, Schilsky RL, Ratain MJ.
    Cancer Res; 1994 Jan 01; 54(1):114-9. PubMed ID: 8261430
    [Abstract] [Full Text] [Related]

  • 13. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
    Blaney SM, Balis FM, Cole DE, Craig C, Reid JM, Ames MM, Krailo M, Reaman G, Hammond D, Poplack DG.
    Cancer Res; 1993 Mar 01; 53(5):1032-6. PubMed ID: 8439950
    [Abstract] [Full Text] [Related]

  • 14. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.
    Clin Cancer Res; 2003 Sep 15; 9(11):4092-100. PubMed ID: 14519631
    [Abstract] [Full Text] [Related]

  • 15. Phase I and pharmacokinetic study of hepsulfam (NSC 329680).
    Hendricks CB, Grochow LB, Rowinsky EK, Forastiere AA, McGuire WP, Ettinger DS, Sartorius S, Lubejko B, Donehower RC.
    Cancer Res; 1991 Nov 01; 51(21):5781-5. PubMed ID: 1933848
    [Abstract] [Full Text] [Related]

  • 16. Phase I clinical and pharmacological study of merbarone.
    Dimaggio JJ, Warrell RP, Muindi J, Stevens YW, Lee SJ, Lowenthal DA, Haines I, Walsh TD, Baltzer L, Yaldaei S.
    Cancer Res; 1990 Feb 15; 50(4):1151-5. PubMed ID: 2297763
    [Abstract] [Full Text] [Related]

  • 17. A phase II trial of piroxantrone in advanced ovarian carcinoma after failure of platinum-based chemotherapy: Southwest Oncology Group Study 8904.
    Albain KS, Liu PY, Hantel A, Poplin EA, O'Toole RV, Wade JL, Maddox AM, Alberts DS.
    Gynecol Oncol; 1995 Jun 15; 57(3):407-11. PubMed ID: 7774846
    [Abstract] [Full Text] [Related]

  • 18. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
    Arteaga CL, Brown TD, Kuhn JG, Shen HS, O'Rourke TJ, Beougher K, Brentzel HJ, Von Hoff DD, Weiss GR.
    Cancer Res; 1989 Aug 15; 49(16):4648-53. PubMed ID: 2743343
    [Abstract] [Full Text] [Related]

  • 19. Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).
    Noe DA, Rowinsky EK, Shen HS, Clarke BV, Grochow LB, McGuire WB, Hantel A, Adams DB, Abeloff MD, Ettinger DS.
    Cancer Res; 1990 Aug 01; 50(15):4595-9. PubMed ID: 2369734
    [Abstract] [Full Text] [Related]

  • 20. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Fields S, Von Hoff DD, Verweij J.
    Clin Cancer Res; 1998 May 01; 4(5):1153-8. PubMed ID: 9607572
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.